ArticleHuman vaccines & immunotherapeutics2026
Safety evaluation of inactivated poliomyelitis vaccine.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to evaluate the safety profile of inactivated poliomyelitis vaccine made from Sabin strains (sIPV) developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, during its post-marketing real-world use in China from 2015 to 2025. A database-based retrospective analysis was conducted using multi-source data, including the Chinese Center for Disease Control and Prevention's (CDC) Adverse Events Following Immunization (AEFI) surveillance system, post-marketing safety studies, and internal vaccination databases. Safety metrics were compared with national IPV (2018-2022) and all marketed vaccines. Statistical analyses employed chi-square and Fisher's exact tests. Among 50,111,746 sIPV doses administered, 12,788 AEFI cases were reported (25.52 per 100,000 doses). sIPV exhibited significantly lower AEFI reported incidences than national IPV data for pyrexia (≥38.6°C) (6.19 vs. 8.51 per 100,000 doses,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.